cobenfy bristol myers squibb - Search News

Bristol-Myers Squibb, Alzheimer's and schizophrenia

Hosted on MSN · 2d

Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the latter part of the year.

Business Insider · 2d

Bristol Myers CEO says new drug Cobenfy effective in schizophrenia, CNBC reports

Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older

BayStreet · 2d

Bristol Myers Points to New Alzheimer Drug

Bristol Myers Squibb (NYSE:BMY) believes Alzheimer’s is the largest market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in revenue. In an interview,

Hosted on MSN · 3d

Feedback on schizophrenia treatment has been great, says Bristol Myers Squibb CEO

Bristol Myers Squibb CEO Christopher Boerner joins 'Mad Money' host Jim Cramer to talk its new schizophrenia treatment Cobenfy, its oncology business, and more.

Bloomberg on MSN · 3d

Bristol Myers Says New Schizophrenia Drug Off to Strong Start

Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, in an early sign that its $14 billion purchase of Karuna Therapeutics is paying off.

2d

Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

NBC Connecticut4d

Bristol Myers Squibb CEO describes new drug for treating schizophrenia

Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat ...

FDA approves first new schizophrenia drug in more than 30 years

The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.

Cambridge Cognition highlights positive Cantab results

Cambridge Cognition believes these findings highlight Cantab’s effectiveness in measuring cognitive performance improvements.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results